Dyspnea, Heart Failure, Pulmonary Disease
Conditions
Keywords
Heart failure, Dyspnea, Heart disease, Pulmonary disease, Natriuretic peptide, Rehabilitation
Brief summary
The objective of this work is to investigate and then to sequence new biomarkers in the plasma of patients presenting with dyspnea secondary or not to heart failure, and study their diagnostic and prognostic value.
Detailed description
Plasma samples for patients with dyspnea, edema, with or without heart failure; ambulatory or admitted for cardiac decompensation (even with cardiac shock and LVAD) ; or entering a cardiac rehabilitation program, will be prospectively collected. The objective of this work is to investigate and then to sequence new proteins in the plasma of these patients for diagnostic and prognostic purpose.
Interventions
None listed
Sponsors
Assistance Publique - Hôpitaux de Paris
University Paris 7 - Denis Diderot
ThermoFisher Scientific Brahms Biomarkers France
Hoffmann-La Roche
Alere San Diego
Servier
Helsinki University Central Hospital
University Hospital, Basel, Switzerland
Massachusetts General Hospital
The Cleveland Clinic
Maastricht University Medical Center
Department of Laboratory Medicine, Konventhospital Barmherzige Brueder, Linz, Austria
Hospital Universitario Virgen de la Arrixaca
University Hospital Monastir, Tunis
Università degli Studi di Brescia
Intensive and Cardiac Care Unit, Nippon Medical School, Tokyo, Japan
Brno University Hospital
University of Cape Town
Institut National de la Santé Et de la Recherche Médicale, France
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients presenting with shortness of breath secondary or not to heart failure, even with cardiac shock and LVAD. * Patients with valvular disease * chronic stable heart failure. * post- partum Cardiomyopathy
Exclusion criteria
* terminal cancer * progressive neurological disease * pregnancy * opposition of the patient
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Long term cardiovascular mortality | Prospective at 12 months | To detect prognostic values of plasma biomarkers, we assess cardiovascular mortality at 3, 6, and 24 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cardiac hospitalization(s) at 3, 6,12 and 24 months | Prospective at 12 months | We assess cardiac morbidity within 3, 6, and 24 months months after admission |
| Diagnostic value of new biomarkers. | at day 0 | Assess accuracy of new biomarkers to discriminate heart failure from non-heart failure (negative and positive predictive values) |
Countries
France
Contacts
Primary ContactAlexandre Mebazaa, PHD
Backup ContactAlain Cohen-Solal, PHD
Outcome results
None listed